Better Health for All

Adicet Bio's core business is the discovery and development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, such as relapsed/refractory aggressive B-cell NHL, systemic sclerosis, and lupus nephritis.

This indicates that the company's entire business is devoted to health improvement, with its product portfolio delivering exceptional health benefits. The lead product, ADI-001, has shown positive efficacy data in Phase 1 trials, with a 71% overall response rate and 63% complete response rate across all dose levels as of June 2023, and has received two FDA Fast Track Designations. As a clinical-stage biotechnology company, Adicet Bio is pre-revenue, meaning it generates zero revenue from products with established negative health outcomes. In terms of safety, ADI-001 was generally well-tolerated in trials, with no dose-limiting toxicities or graft-versus-host disease reported, and only one Grade 3 or higher Cytokine Release Syndrome and one Immune effector cell-associated neurotoxicity syndrome event in 24 efficacy-evaluable patients as of June 2023. The company's R&D expenses were $22.8 million in Q1 2025 and $99.3 million in FY 2024, but the proportion of this investment specifically aimed at improving health outcomes and accessibility is not provided. While clinical trials are ongoing, no specific data on the ethical conduct of these trials is available.

Fair Money & Economic Opportunity

Adicet Bio, Inc. is a biotechnology company focused on developing cell therapies for cancer.

Its core business does not involve providing financial services such as lending, deposits, or insurance to consumers. Therefore, the company does not engage in activities related to customer demographics for financial inclusion, pricing structures for financial products, revenue from high-cost financial products, financial inclusion initiatives, customer financial data, fair lending practices, impact on customer wealth building, community finance reinvestment, financial literacy programs, consumer debt products, financial service access points, or financial product disclosures. All KPIs for the 'Fair Money & Economic Opportunity' value are thus not applicable.

Fair Pay & Worker Respect

Adicet Bio's employee engagement score is 3.4 out of 5 stars based on 46 reviews, with 57% of employees recommending working there to a friend.

This translates to approximately 68/100, which maps to a score of -10. Voluntary employee turnover is described as high in several reviews, with one stating "Everyone I know wants to leave" and another mentioning "Recent layoffs have been difficult," which aligns with a turnover rate of 25-30%, scoring -30. There are no specific regulatory actions, violations, fines, or compliance issues mentioned in the articles, resulting in a score of -10 for labor violation incidents. However, there are mentions of a part-time contractor position and employees being pressured to work off the clock without pay, with some working multiple 12-hour days without compensation as exempt employees. This indicates a portion of the workforce on insecure contracts or experiencing issues related to contract terms, which maps to a score of -50.

Honest & Fair Business

Adicet Bio, Inc. has reported no regulatory fines in the past three years and represents that it has not received any material warning letters or notices of non-compliance from regulatory authorities.

The company has a comprehensive whistleblower policy, approved in August 2022, which applies globally to all employees and explicitly forbids retaliation. It offers a 24/7 anonymous hotline and online reporting managed by a third-party, with acknowledgement of concerns within 7 days and further feedback within 3 months. The company identified a material weakness in internal controls over financial reporting related to unauthorized cash disbursements in Q4 2024, which was remediated by March 6, 2025. Adicet Bio represents that it has instituted and maintained policies and procedures designed to comply with Anti-Corruption Laws, including the FCPA and UK Bribery Act 2010. The company relies on certificates of public officials and officers for matters of fact, and legal opinions from external counsel for certain intellectual property matters, indicating limited third-party verification of ethical claims.

Kind to Animals

Adicet Bio, Inc. conducts in vivo studies using immunodeficient NSG mice for the development of its allogeneic gamma delta T cell therapies, as evidenced in research articles detailing the testing of ADI-270 and GPC-3.CAR/sIL-15 Vδ1 T cells.

One article mentions collaboration with Regeneron Pharmaceuticals, Inc. for the development of these therapies. However, the provided articles do not offer specific quantitative data on the number of animals used, the percentage of non-animal testing methods employed, or any details regarding animal welfare policies, certifications, or investments in animal-free alternatives. Therefore, most KPIs related to animal welfare cannot be assessed.

No War, No Weapons

Adicet Bio, Inc. is a biotechnology company focused on developing cell therapies for cancer and autoimmune diseases. The provided articles, which include financial reports and ESG summaries, explicitly state that no information is available regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other activities related to the 'No War, No Weapons' value.

Therefore, no KPIs under this value can be scored based on the available evidence.

Safe & Smart Tech

The provided article, a summary of Adicet Bio, Inc.'s 2024 10-K filing, lacks the specific quantitative data required by the rubric to assess the company's performance across the 'Safe & Smart Tech' KPIs.

While it mentions the company utilizes third-party IT and security providers for penetration testing and threat intelligence, implements employee security awareness training, and has a cybersecurity risk management program informed by industry standards, these statements do not include the necessary percentages, dollar amounts, numbers, or dates to map to any specific score tiers. The report also states that cybersecurity threats have not materially affected the company, but this is not a sufficiently precise data point to score data breach severity against the rubric's defined timeframes and impact levels. No information is provided regarding AI ethics governance, privacy certifications, encryption implementation, AI audit practices, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty effectiveness, privacy by design, data minimization, regulatory compliance details, algorithmic harm remediation, or digital rights advocacy.

Zero Waste & Sustainable Products

Adicet Bio has set a waste reduction target of 17.6 metric tons, alongside targets for a 15% reduction in laboratory energy usage by 2025, a 53,338 gallons/month water usage target, and a 35% reduction in GHG emissions by 2026.

The company has implemented waste reduction strategies across three research facilities and invested $2.3 million in manufacturing sustainability in 2023. It has achieved a 28% reduction in single-use plastic consumption.